Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etripamil Nasal Spray in Atrial Fibrillation with Rapid Ventricular Rate
NCT06716021Phase 3Recruiting
- Sponsor
- Milestone Pharmaceuticals
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Placebo with Etripamil (2 arms). Primary endpoint: Efficacy of etripamil NS over placebo at 30 months. Started Aug 2026; status: recruiting.
02
Drugs
etripamil
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06716021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06716021.